Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan 6;7(1):6.
doi: 10.3390/pathogens7010006.

What Could Be the Role of Antifungal Lock-Solutions? From Bench to Bedside

Christine Imbert  1   2 , Blandine Rammaert  3   4   5
Affiliations
Review

What Could Be the Role of Antifungal Lock-Solutions? From Bench to Bedside

Christine Imbert et al. Pathogens. .

Abstract

Candidemia related to the presence of a biofilm are often reported in patients with vascular catheters. Once they are mature, biofilms are persistent infectious reservoirs, and the yeasts dispersed from biofilms can cause infections. Sessile yeasts typically display increased levels of resistance to most antimicrobial agents and systemic treatments usually fail to eradicate previously formed fungal biofilms. In a curative strategy, antifungal lock therapy may help to sterilize catheters, with very high concentrations of antifungal agents, which are not compatible with systemic use. This strategy has been studied by several authors in in vitro and in vivo studies, and more rarely, in clinical settings for adult and paediatric patients. Our study aims to assess the efficacy of the antifungal solutions used for lock therapy and demonstrated by the different teams.

Keywords: antifungal agents; biofilm; candidemia; catheter carrier patient.

PubMed Disclaimer

Conflict of interest statement

B.R. received speaker fees from Gilead, Basilea, Merck, Astellas, and travel grant for conferences from Pfizer. C.H. received speaker fees from Gilead and travel grants for conferences from Astellas, Pfizer and Gilead.

References

    1. Mayer F.L., Wilson D., Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013;4:119–128. doi: 10.4161/viru.22913. - DOI - PMC - PubMed
    1. Nikawa H., Nishimura H., Hamada T., Makihira S., Samaranayake L.P. Relationship between thigmotropism and Candida biofilm formation in vitro. Mycopathologia. 1998;144:125–129. doi: 10.1023/A:1007073930933. - DOI - PubMed
    1. Hirota K., Yumoto H., Sapaar B., Matsuo T., Ichikawa T., Miyake Y. Pathogenic factors in Candida biofilm-related infectious diseases. J. Appl. Microbiol. 2017;122:321–330. doi: 10.1111/jam.13330. - DOI - PubMed
    1. Costerton J.W., Stewart P.S., Greenberg E.P. Bacterial biofilms: A common cause of persistent infections. Science. 1999;284:1318–1322. doi: 10.1126/science.284.5418.1318. - DOI - PubMed
    1. Mukherjee P.K., Chandra J. Candida biofilm resistance. Drug Resist. Updat. 2004;7:301–309. doi: 10.1016/j.drup.2004.09.002. - DOI - PubMed

LinkOut - more resources